DE69930243T2 - Behandlung iatrogenen und altersbedingten bluthochdruck mit vitamin b6-derivative, und pharmazeutische zusammensetzungen verwendbar dazu - Google Patents

Behandlung iatrogenen und altersbedingten bluthochdruck mit vitamin b6-derivative, und pharmazeutische zusammensetzungen verwendbar dazu Download PDF

Info

Publication number
DE69930243T2
DE69930243T2 DE69930243T DE69930243T DE69930243T2 DE 69930243 T2 DE69930243 T2 DE 69930243T2 DE 69930243 T DE69930243 T DE 69930243T DE 69930243 T DE69930243 T DE 69930243T DE 69930243 T2 DE69930243 T2 DE 69930243T2
Authority
DE
Germany
Prior art keywords
nsaid
use according
vitamin
group
indomethacin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69930243T
Other languages
German (de)
English (en)
Other versions
DE69930243D1 (de
Inventor
Krishnamurti Winnipeg DAKASHINAMURTI
Rajat Winnipeg SETHI
S. Naranjan Winnipeg DHALLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Medicure Inc
Original Assignee
University of Manitoba
Medicure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba, Medicure Inc filed Critical University of Manitoba
Publication of DE69930243D1 publication Critical patent/DE69930243D1/de
Application granted granted Critical
Publication of DE69930243T2 publication Critical patent/DE69930243T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE69930243T 1998-04-16 1999-04-16 Behandlung iatrogenen und altersbedingten bluthochdruck mit vitamin b6-derivative, und pharmazeutische zusammensetzungen verwendbar dazu Expired - Fee Related DE69930243T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61173 1998-04-16
US09/061,173 US6051587A (en) 1998-04-16 1998-04-16 Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
PCT/CA1999/000331 WO1999053928A1 (en) 1998-04-16 1999-04-16 Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein

Publications (2)

Publication Number Publication Date
DE69930243D1 DE69930243D1 (de) 2006-05-04
DE69930243T2 true DE69930243T2 (de) 2006-12-07

Family

ID=22034118

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69930243T Expired - Fee Related DE69930243T2 (de) 1998-04-16 1999-04-16 Behandlung iatrogenen und altersbedingten bluthochdruck mit vitamin b6-derivative, und pharmazeutische zusammensetzungen verwendbar dazu

Country Status (12)

Country Link
US (1) US6051587A (https=)
EP (1) EP1071430B1 (https=)
JP (1) JP2002512194A (https=)
AT (1) ATE319457T1 (https=)
AU (1) AU765749B2 (https=)
BR (1) BR9909672A (https=)
CA (1) CA2328730C (https=)
DE (1) DE69930243T2 (https=)
ES (1) ES2260906T3 (https=)
IL (1) IL139681A0 (https=)
NZ (1) NZ508142A (https=)
WO (1) WO1999053928A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
US6339085B1 (en) 1999-03-08 2002-01-15 The University Of Manitoba Therapeutics for cardiovascular and related diseases
US6489345B1 (en) * 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
EP1872797A3 (en) 1999-08-24 2008-04-02 Medicure International Inc. Treatment of cardiovascular and related pathologies
EP1531157B1 (en) * 2000-02-29 2008-03-19 Medicure International Inc. Cardioprotective phosphonates
US7442689B2 (en) 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
AU3718501A (en) 2000-02-29 2001-09-12 Medicure Int Inc Cardioprotective phosphonates and malonates
WO2001072309A2 (en) 2000-03-28 2001-10-04 Medicure International Inc. Treatment of cerebrovascular disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
WO2002039994A2 (en) 2000-11-20 2002-05-23 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
EP2392562B1 (en) 2002-07-29 2018-03-07 Cardax Pharma, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
WO2004084910A1 (en) * 2003-03-27 2004-10-07 Medicure Inc. Compositions for treating angina
EP1610783A2 (en) * 2003-03-27 2006-01-04 Medicure Inc. Modulation of cell death
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
EP1750723A1 (en) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
US20060019929A1 (en) * 2004-07-07 2006-01-26 Albert Friesen Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
CA2575849A1 (en) * 2004-08-10 2006-02-16 Medicure International Inc. Combination therapies employing vitamin b6 related compounds and ace inhibitors and uses thereof for the treatment of diabetic disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
WO2006050598A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
EP1827455A1 (en) * 2004-11-26 2007-09-05 Medicure International Inc. Novel formulation of pyridoxal 5'-phosphate and method of preparation
JP2008526783A (ja) * 2005-01-05 2008-07-24 メディキュア・インターナショナル・インコーポレーテッド トリグリセリドレベルを調節するための化合物及び方法
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
CA2503087A1 (en) * 2005-03-30 2006-09-30 Medicure International Inc. Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
JP2009517411A (ja) * 2005-11-28 2009-04-30 メディキュア インターナショナル インコーポレーテッド 心血管及び関連病状の処置のための調剤
DOP2007000055A (es) 2006-04-10 2007-10-31 Senosiain S A De C V Lab Composición farmaceutica que comprende un analgésico y vitaminas
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
MX2008003230A (es) * 2008-03-07 2009-09-07 Senosiain S A De C V Lab Composicion famaceutica oral que comprende la combinacion de una sal de ketorolaco y vitaminas del complejo b.
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
WO2014063134A1 (en) * 2012-10-19 2014-04-24 New York University Methods for inhibiting osteolysis
RU2629367C1 (ru) * 2016-11-02 2017-08-29 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Нестероидное противовоспалительное средство на основе напроксена, обладающее низкой гастротоксичностью

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4492M (https=) * 1965-07-07 1966-10-10
FR6707M (https=) * 1966-04-29 1969-02-17
FR6723M (https=) * 1966-12-30 1969-02-17
FR7503M (https=) * 1967-05-30 1969-12-08
GB1236531A (en) * 1969-02-12 1971-06-23 Soc D Etudes Prod Chimique Adenin derivative
JPS53121765A (en) * 1977-04-01 1978-10-24 Chugai Pharmaceut Co Ltd Pyridoxal derivatives
IL62602A (en) * 1980-05-19 1984-06-29 Labaz Sanofi Nv Pyridoxine derivatives,their preparation and pharmaceutical compositions containing them
US4542026A (en) * 1983-04-29 1985-09-17 Jose Rios Method of treating vasomotor disorders
US4564614A (en) * 1984-10-11 1986-01-14 Pfizer Inc. Antiinflammatory methods
FR2641189B1 (fr) * 1988-06-20 1991-05-10 Timol Mamoojee Compositions pharmaceutiques contenant de l'acide acetyl salicylique et de la vitamine b6
US20040180865A1 (en) * 1993-06-04 2004-09-16 Jeffry W. Kreamer Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease

Also Published As

Publication number Publication date
EP1071430A1 (en) 2001-01-31
CA2328730C (en) 2007-08-21
AU765749B2 (en) 2003-09-25
WO1999053928A1 (en) 1999-10-28
DE69930243D1 (de) 2006-05-04
CA2328730A1 (en) 1999-10-28
NZ508142A (en) 2002-11-26
BR9909672A (pt) 2007-07-31
ES2260906T3 (es) 2006-11-01
AU3402999A (en) 1999-11-08
JP2002512194A (ja) 2002-04-23
US6051587A (en) 2000-04-18
IL139681A0 (en) 2002-02-10
ATE319457T1 (de) 2006-03-15
EP1071430B1 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
DE69930243T2 (de) Behandlung iatrogenen und altersbedingten bluthochdruck mit vitamin b6-derivative, und pharmazeutische zusammensetzungen verwendbar dazu
DE60132723T2 (de) Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
DE68905096T2 (de) Niacin und guar-mehl enthaltende zusammensetzung.
DE69734405T2 (de) Verwendung von CS-866 (Olmersartan) zur Herstellung eines Medikaments für die Behandlung von Arteriosklerose
DE69432644T2 (de) Kombination eines Angiotensin-II antagonistisch wirkendes Benzimidazols mit ein Diuretikum
DE69624699T2 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
DE3428729A1 (de) Mittel zur verhinderung oder inhibierung einer alveolaeren knochenresorption
DE3786893T2 (de) Piperidinderivat zur Schmerzbehandlung.
DE3390114C2 (https=)
AT389998B (de) Verfahren zur herstellung einer analgetischen und antiinflammatorischen pharmazeutischen zubereitung
DE69725879T2 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
DE69420776T2 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
DE69605531T2 (de) Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans
EP0087864B1 (en) Pharmaceutical composition
DE3511609C2 (https=)
DE69501421T2 (de) Hematetrenome Derivat als antiarteriosklerotisches Mittel
DE69132782T2 (de) Verwendung von angiotensin-ii-antagonisten in der behandlung der linken ventrikulären hypertrophie
DE60203844T2 (de) Verwendung von Hydantoin und seinen Derivaten gegen Hypalbuminämie
DE60206169T2 (de) Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff
DE3739779A1 (de) Pharmazeutische praeparate
DD242749A5 (de) Verbesserte entzuendungshemmende zusammensetzungen und verfahren
EP1001756A1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
DE69533742T2 (de) Verwendung von Prolin und/oder Derivaten als Mittel gegen Hepatitis
DE69909395T2 (de) Zusammensetzung mit ketanserin und carnitin zur behandlung von crps
EP0820771A2 (de) Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und eine Magnesiumverbindung enthält

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee